Novartis, Bristol Myers Halt Autoimmune CAR-T Trials Due to Safety Concerns
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events. Side effects observed in testing have led Novartis to halt development.
NovartisBristol Myers Squibb
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Side effects observed in testing have led Novartis to halt development”
biopharma dive — Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns“Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events”
fierce biotech — <a href="/biotech/novartis-bristol-myers-squibb-halt-car-t-cell-trials-due-immune-events" hreflang="en">Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events</a>